Markets

Innovent's SYCUME Delivers Phase 3 Win In Inactive Thyroid Eye Disease

October 08, 2026 — 10:59 pm EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Innovent's SYCUME Delivers Phase 3 Win in Inactive Thyroid Eye Disease

Thursday, Innovent Biologics (1801.HK) said its Phase 3 RESTORE-3 study met the primary endpoint in patients with inactive thyroid eye disease (TED), with SYCUME (teprotumumab N01 Injection) demonstrating significant improvements in eye portrusion compared with placebo.

SYCUME achieved a 60.4% proptosis response rate and a mean reduction of 1.88 mm in eye protrusion at Week 24, while maintaining a favorable safety profile.

The therapy is the first IGF-1R antibody approved in China and the second one approved worldwide for TED. It is now included in China's National Reimbursement Drug List.

Inactive TED patients account for roughly two-thirds of the overall TED population, representing a significant unmet medical need.

1801.HK is currently trading at $90.35, down 2.43%

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Markets
Stocks Mentioned

Latest Articles
Data is currently not available